RecruitingPlaque Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Eligible age

40+ yrs

Accepts

All genders

Locations

33 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Sponsor: Bristol-Myers Squibb

✓ Participants with moderate-to-severe plaque psoriasis:
✓ 1. Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab;
✓ 2. Have at least 1 of the following cardiovascular risk factors:
✓ Current cigarette smoker
✓ Diagnosis of hypertension
✓ Diagnosis of hyperlipidemia
✓ Diabetes mellitus type 1 or 2
✓ History of one or more of the following cardiovascular events: Coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heart attack), cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke, or transient ischemic attack

✕ Participants must not have recent history of 1 of the following cardiovascular events: MI, stroke, or coronary revascularization, or VTE within 90 days prior to Day 1.
✕ Participants must not have unstable CVD, defined as a recent clinical cardiovascular event (eg, unstable angina, rapid atrial fibrillation), or a cardiac hospitalization (eg, pacemaker implantation, HF) within 90 days prior to Day 1.
✕ Participants must not have evidence of active cancer or history of cancer (solid organ or hematologic malignancy including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has been treated with no evidence of recurrence).
✕ Other protocol define inclusion/exclusion criteria apply.